Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumours (MK-3475-158/KEYNOTE-158)

Official Title

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumours (KEYNOTE 158)


In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumours that have progressed on standard of care therapy will be treated with pembrolizumab.

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR)
Secondary Outcome:
  • Duration of Response (DOR)
  • Progression Free Survival (PFS)
  • Overall Survival (OS)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society